Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Thymosin Alpha-1 structure

Thymosin Alpha-1

Immune
Approved Research
80%
Low Risk
1/5

Dosing Protocol

Typical Dose 1.6 mg
Range 1.6 - 6.4 mg
Maintenance 1.6 mg 2x weekly

Pharmacokinetics

Half-Life 2.0 hrs
Onset 30 min
Peak 1.5 hrs
Duration 6.0 hrs
Bioavailability 85%
Primary Route Subcutaneous

Administration

Routes Subcutaneous
Injection Sites Abdomen, Thigh, Deltoid
Needle Gauge 27-29G
Syringe Type Insulin
Timing Morning

Reconstitution

Diluent Sterile Water
Volume 1 mL
Stability 14 days refrigerated
Vial Sizes 1.6, 3.2 mg

Special Instructions

Well-established safety in clinical use. Approved in 35+ countries for hepatitis and cancer adjuvant therapy.